DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.
Pasi A Jänne, Cai-Cun Zhou, Egbert F Smit...
https://pubmed.ncbi.nlm.nih.gov/42682104/Actively Recruiting
Led by Daiichi Sankyo · Updated on 2026-10-23
686
Participants Needed
246
Research Sites
135 weeks
Total Duration
Researchers are studying treatments for adults with locally advanced unresectable or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors overexpress HER2 and have PD-L1 TPS less than 50%. This trial compares the combination of trastuzumab deruxtecan T-DXd with pembrolizumab against platinum-based chemotherapy combined with pembrolizumab. Participants have not received prior therapy for their advanced or metastatic NSCLC and lack known actionable genomic alterations with available targeted treatments. The study involves two treatment groups. One group receives T-DXd at 5.4 mgkg intravenously every three weeks alongside pembrolizumab at 200 mg IV every three weeks. The other group receives pemetrexed at 500 mgm IV every three weeks plus a platinum chemotherapy agent cisplatin or carboplatin combined with pembrolizumab at 200 mg IV every three weeks. Treatment continues as per protocol for first-line therapy in this population. Participants will be monitored regularly for disease progression and survival outcomes, with progression-free survival assessed by independent central review up to approximately 54 months and overall survival up to about 85 months. Tumor tissue samples will be assessed for HER2 and PD-L1 expression. Safety and treatment effects will be evaluated throughout the study, which may last several years until study completion in 2032.
CONDITIONS
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
C
Contact for Trial Information
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Daiichi Sankyo
Lead Sponsor
Merck Sharp & Dohme LLC
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational: T‑DxD + Pembrolizumab | Control: Chemo‑immunotherapy |
|---|---|---|
| What it is | Combination of trastuzumab deruxtecan (HER2‑directed antibody‑drug conjugate) with pembrolizumab as first‑line treatment | Pembrolizumab plus platinum‑based chemotherapy and pemetrexed as standard first‑line therapy |
| Role in trial | Evaluational investigational arm combining HER2‑targeted agent with immunotherapy | Active comparator reflecting current standard chemo‑immunotherapy |
| Primary use | First‑line treatment for HER2‑overexpressing advanced non‑small cell lung cancer | Existing first‑line standard therapy for non‑squamous NSCLC without actionable mutations |
| Administration | Intravenous trastuzumab deruxtecan 5.4 mg/kg plus pembrolizumab 200 mg every 3 weeks | Intravenous pembrolizumab 200 mg plus pemetrexed 500 mg/m² and cisplatin or carboplatin every 3 weeks |
| Evidence status | Efficacy and safety are being evaluated; outcomes not yet available | Standard chemo‑immunotherapy is supported by existing real‑world and trial data |
| Important risks | Not yet established; safety profiles under evaluation | Known toxicities from chemotherapy and immunotherapy combinations |
| Important limitations | Unknown efficacy and safety; not yet approved, limited to trial participants | Efficacy may depend on PD‑L1 expression levels; patients with low PD‑L1 may have poorer outcomes |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are evaluated to confirm eligibility for the trial, including medical history, tumor testing, and consent procedures.
1 to 2 visits as needed
Duration - Up to approximately 54 months
Participants receive either trastuzumab deruxtecan plus pembrolizumab or platinum-based chemotherapy plus pembrolizumab, administered intravenously every 3 weeks.
Every 3 weeks
Duration - Up to approximately 85 months
Participants are monitored for disease progression and overall survival after treatment ends, with assessments continuing up to about 85 months from randomization.
Regular follow-up visits as scheduled
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Pasi A Jänne, Cai-Cun Zhou, Egbert F Smit...
https://pubmed.ncbi.nlm.nih.gov/42682104/Daiichi Sankyo
Lead Sponsor
Merck Sharp & Dohme LLC
Collaborating Sponsor